Understanding the Rapidly Evolving Science and Best Practices in Multiple Myeloma


February 18th, 2020 - February 18th, 2021

Overview

Multiple myeloma is the second-most common blood cancer in the United States, with an estimated 32,110 new cases and 12,960 related deaths anticipated in 2019.  Despite substantial progress in treatment, prognosis and survival remain suboptimal in this disease, which is marked by substantial morbidity and reduced quality of life. Providers who participate in focused and expert-guided education will be better prepared to implement best practices and to help patients make better-informed decisions about their care in collaboration with their health care team. 

Target Audience
This activity has been designed to meet the educational needs of physicians, nurse practitioners (NPs), physician assistants (PAs) and oncology nurses who manage patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the burden of multiple myeloma in the US

  • Apply current best practices for myeloma assessment based current standards and emerging advances

  • Select optimal treatment for multiple myeloma based on current guideline recommendations and expert opinion regarding emerging data

  • Summarize the latest developments in myeloma treatment that have changed management options for patients with myeloma

  • Devise treatment plans for multiple myeloma with consideration for age/frailty and other patient and disease characteristics

Activity Launch Date - 2/18/2020
Expiration Date - 2/18/2021


Supporter Acknowledgment Statement
This activity is supported by an educational grant from Sanofi Genzyme, Karyopharm, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies.  It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes.  To that end, we welcome comments about how to better serve your needs.

Copyright Information
Copyright 
© 2020 - All rights reserved. This CME-certified program is held as copyrighted by Horizon CME. Through this notice, Horizon CME grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.